The best partnerships aren't dependent on a mere common goal but on a shared path of equality, desire, and no small amount of passion.
— Sarah MacLean
At Elpiscience, we believe that strong strategic partnerships enable us to deliver innovative therapeutics to improve people’s lives. Our ethos is to create long-term mutually beneficial relationships. We synergistically collaborate with global biotech companies, academic institutions and clinicians to accelerate the promise of immunotherapy, advance development programs and deliver quality and novel therapies to patients.
We have partnered with Inhibrx to in-license their bispecific antibody targeting 4-1BB and PD-L1 (ES101/ INBRX-105), and their agonistic OX40 antibody (ES102/ INBRX-106). Elpiscience has greater China rights to these compounds, while Inhibrx holds U.S and other global rights.
We are collaborating with Bio-Techne, a global leader in life sciences and molecular diagnostics, for the co-development of novel immunotherapies. Under the terms of the agreement, Elpiscience will have access to diverse high-quality antibodies from Bio-Techne’s antibody library for use in preclinical, clinical and commercial pharmaceutical development.